Your browser doesn't support javascript.
loading
Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen, Suzanne; Bruno, Raimondo; Degenhardt, Louisa; Demirkol, Apo; Lintzeris, Nicholas.
Afiliação
  • Nielsen S; National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia.
  • Bruno R; University of Sydney, Discipline of Addiction Medicine, Sydney, Australia.
  • Degenhardt L; Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia.
  • Demirkol A; National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia.
  • Lintzeris N; School of Medicine, University of Tasmania, Hobart, Australia.
Drug Alcohol Rev ; 36(3): 311-316, 2017 05.
Article em En | MEDLINE | ID: mdl-27273511
ABSTRACT

INTRODUCTION:

Use of opioid agonist treatments for prescription opioid (PO) dependence is rapidly increasing. Current guidelines are based on research with heroin users. This study aimed to examine methadone and buprenorphine dose requirements for PO-dependent people. DESIGN AND

METHODS:

A retrospective case series of PO-dependent patients entering methadone and buprenorphine treatment. Daily oral morphine equivalent (OME) doses at baseline were calculated using standard dose conversion calculations. Dose conversion tables were used to estimate opioid agonist doses, based on starting dose of PO. Baseline methadone and buprenorphine dose at days 7 and 28 were examined. Linear models were fit to the data.

RESULTS:

Participants (n = 44) were 67% male, mean age 41 years (SD 10 years); 69% reported a pain condition. The methadone group (n = 21) had a mean PO dose of 704.5 mg OME (SD 783.5 mg) prior to treatment, and mean methadone dose of 45.3 mg (SD 13.1 mg) at day 7 and 61.6 mg (SD 20.8 mg) at day 28. The buprenorphine group (n = 23) had a mean PO dose of 771.7 mg OME (SD 867.7 mg) prior to treatment, with a mean dose of 14.6 mg (SD 8.3 mg) at day 7 and 18.1 (SD 8.9 mg) at day 28. Linear relationships were not found between OME and opioid agonist dose.

CONCLUSIONS:

Opioid agonist dosages varied substantially between individuals, and from predicted dosages based on dose conversion tables. Use of conversion tables to guide selection of opioid agonist dosage may compromise patient safety. [Nielsen S, Bruno R, Degenhardt L, Demirkol A, Lintzeris N. Opioid agonist doses for oxycodone and morphine dependence Findings from a retrospective case series Drug Alcohol Rev 2017;36311-316].
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Oxicodona / Tratamento de Substituição de Opiáceos / Analgésicos Opioides / Dependência de Morfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Drug Alcohol Rev Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Oxicodona / Tratamento de Substituição de Opiáceos / Analgésicos Opioides / Dependência de Morfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Drug Alcohol Rev Ano de publicação: 2017 Tipo de documento: Article